Research Paper Volume 12, Issue 21 pp 21147—21160

Melatonin exerts immunoregulatory effects by balancing peripheral effector and regulatory T helper cells in myasthenia gravis


Figure 2. Melatonin decreased Th1 and Th17 cell responses. (A) Alterations in the production of signature Th1 cytokines, including IL-2, IFNγ and TNFα, after melatonin treatment in different MG subgroups. (B) Levels of IL-17A in response to melatonin treatment (HC, n=10; NIST-MG, n=13; IST-MG, n=15). (C) The frequency of CD4+ T cells expressing either IFNγ or (D) TNFα in melatonin-treated PBMCs from MG patients and HCs. (E) The frequency of CD4+ T cells expressing IL-17A in melatonin-treated PBMCs (HC, n=10; MG, n=10). The data are presented as the mean ± SD. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.